TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 1 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $702,000 | -72.3% | 1,462,093 | -22.7% | 0.00% | -100.0% |
| Q1 2019 | $2,535,000 | -10.8% | 1,892,025 | -24.8% | 0.00% | 0.0% |
| Q4 2018 | $2,843,000 | -59.1% | 2,516,272 | -0.1% | 0.00% | -66.7% |
| Q3 2018 | $6,949,000 | -11.5% | 2,517,623 | +14.4% | 0.00% | 0.0% |
| Q2 2018 | $7,855,000 | +39.6% | 2,200,413 | +20.1% | 0.00% | +50.0% |
| Q1 2018 | $5,627,000 | -37.2% | 1,832,741 | +28.8% | 0.00% | -50.0% |
| Q4 2017 | $8,966,000 | -10.3% | 1,423,174 | -2.6% | 0.00% | 0.0% |
| Q3 2017 | $9,998,000 | +27.3% | 1,461,807 | +32.7% | 0.00% | 0.0% |
| Q2 2017 | $7,853,000 | +34.7% | 1,101,255 | +73.6% | 0.00% | +33.3% |
| Q1 2017 | $5,829,000 | +539.1% | 634,300 | +180.4% | 0.00% | – |
| Q4 2016 | $912,000 | +618.1% | 226,222 | +580.4% | 0.00% | – |
| Q3 2016 | $127,000 | +16.5% | 33,250 | +30.6% | 0.00% | – |
| Q2 2016 | $109,000 | -7.6% | 25,450 | 0.0% | 0.00% | – |
| Q1 2016 | $118,000 | – | 25,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |